Critical Issues on Full Critical Issues on Full-
- Length Articles
Critical Issues on Full- - Critical Issues on Full Length Articles - - PowerPoint PPT Presentation
Critical Issues on Full- - Critical Issues on Full Length Articles Length Articles Objectives Objectives How to Read Scientific Manuscripts How to Read Scientific Manuscripts Critical Issues for Research Articles Critical Issues
– – Experiments, in which a maneuver is performed on an Experiments, in which a maneuver is performed on an animal or a volunteer in artificial and controlled animal or a volunteer in artificial and controlled surroundings surroundings – – Clinical trials, in which an intervention, such as a drug Clinical trials, in which an intervention, such as a drug treatment, is offered to a group of patients to determine treatment, is offered to a group of patients to determine what happens to them what happens to them – – Surveys, in which something is measured in a group of Surveys, in which something is measured in a group of patients, health professionals, or some other sample of patients, health professionals, or some other sample of individuals individuals
Narrative Review Narrative Review Systematic Review Systematic Review Question Question Often broad in scope Often broad in scope Often a focused clinical Often a focused clinical question question Sources and Sources and search search Not usually specified, Not usually specified, potentially biased potentially biased Comprehensive sources and Comprehensive sources and explicit explicit Selection Selection Not usually specified, Not usually specified, potentially biased potentially biased Criterion Criterion-
based selection, uniformly applied uniformly applied Appraisal Appraisal Variable Variable Rigorous critical appraisal Rigorous critical appraisal Synthesis Synthesis Often qualitative Often qualitative Quantitative Quantitative Inferences Inferences Sometimes evidence Sometimes evidence-
biased Usually evidence Usually evidence-
based
– – Such as cancer and the acquired immunodeficiency Such as cancer and the acquired immunodeficiency syndrome (AIDS) syndrome (AIDS)
DATA SYNTHESIS: Valsartan, a selective antagonist for angiotensin receptor subtype 1, is the first ARB to be approved angiotensin receptor subtype 1, is the first ARB to be approved for for use in chronic heart failure. Clinical trial data support valsar use in chronic heart failure. Clinical trial data support valsartan as tan as an alternative to angiotensin an alternative to angiotensin-
converting enzyme (ACE) inhibitors in ACE inhibitor in ACE inhibitor-
intolerant patients with chronic heart failure. Valsartan is generally well tolerated, with renal impairment, Valsartan is generally well tolerated, with renal impairment, elevated serum elevated serum creatinine creatinine and potassium levels, and dizziness and potassium levels, and dizziness being the most common adverse effects; consequently, patients being the most common adverse effects; consequently, patients experiencing those adverse events while taking ACE inhibitors ar experiencing those adverse events while taking ACE inhibitors are e likely to experience them with valsartan. Although further study likely to experience them with valsartan. Although further study is is needed, differences in effectiveness among races may exist with needed, differences in effectiveness among races may exist with use of valsartan; however, at this time, valsartan is recommende use of valsartan; however, at this time, valsartan is recommended d as an alternative to ACE inhibitors regardless of race. as an alternative to ACE inhibitors regardless of race. Candesartan Candesartan and losartan have been studied in similar settings. and losartan have been studied in similar settings. Candesartan's Candesartan's data support its use in heart failure; however, data support its use in heart failure; however, losartan's losartan's data have data have been less consistent. been less consistent.
7.10